Solid phase synthesis has revolutionized the manufacture of peptides and oligonucleotides for research, diagnostics, and therapeutics, offering unparalleled efficiency and control over product quality at the industrial scale. For compounds such as Fmoc-Gly-OH in peptide synthesis (CAS 75521-20-1, MW 247.24, formula C15H13NO4), and phosphoramidites in oligonucleotide assembly, the application of automated solid phase techniques provides a robust path to highly pure, well-characterized products suitable for regulated markets. Achieving a yield upwards of 82% with HPLC purity greater than 98% and guaranteed by a reliable global supplier underscores the competitive advantages of these methods.
The automation of solid phase synthesis brings new dimensions to the industrial production of complex biologics. Peptides and oligonucleotides are encoded by their sequences, where stereochemistry and chemoselectivity critically determine function and safety. As assembly proceeds amino acid by amino acid or nucleotide by nucleotide, protecting groups are selectively removed, and couplings are executed under precisely defined conditions. Technical Insights specializes in scaling these technologies, ensuring reproducibility, cGMP compliance, and highest industry standards from research quantities to multi-kilogram lots.
Beginning with the industrial-scale workflow, the process initiates with the pre-loading of a resin, such as Wang or Rink Amide MBHA (for peptides), or controlled-pore glass (CPG) for oligonucleotides. The resin is swollen in N,N-dimethylformamide (DMF) at room temperature (20–25°C) for 30 minutes to allow optimal accessibility to functional groups. The first coupling step involves activation of an Fmoc-protected amino acid (or a DNA phosphoramidite monomer for oligonucleotides) using efficient coupling reagents like HBTU or ETT in DMF, in the presence of N-methylmorpholine as a base. Reaction mixtures are mixed for 30 to 60 minutes at temperatures maintained between 20°C and 25°C to ensure complete coupling, monitored in real-time by quantitative ninhydrin or trityl cation release assays.
Following coupling, the system is drained and thoroughly washed with DMF to ensure removal of excess reagents. Deprotection of the N-terminal Fmoc or DMT group proceeds with 20% piperidine in DMF (for peptides) or 3% dichloroacetic acid in toluene (for oligonucleotides), applied at room temperature for 5–10 minutes, after which the cycle repeats for each building block. After chain assembly, the final cleavage and side chain deprotection require specific conditions; for peptides, a trifluoroacetic acid (TFA) cocktail is used at 0°C to 4°C for 2–3 hours, while for oligonucleotides, concentrated aqueous ammonia treatment at 55°C for 8 hours is common. The crude product is precipitated by slow addition to cold diethyl ether or n-butanol with vigorous stirring, controlling pH to 8–9 for oligonucleotides, to enable product crystallization.
These operations routinely provide isolated yields of 82% or better, confirmed by analytical HPLC with purity greater than or equal to 98%. Structure and purity are verified by analytical methods, and for representative peptides, the 1H NMR (400 MHz, DMSO-d6) might show chemical shifts at delta 7.12 (d, J = 8.4 Hz, 2H), 7.35 (t, J = 7.6 Hz, 2H), 4.22 (q, J = 6.8 Hz, 1H), and 2.19 (s, 3H), supporting structural assignment.
Manufacturing under current Good Manufacturing Practices (cGMP) requires rigorous process validation, traceability, and documentation at each phase. Complete Certificates of Analysis (COA) accompany each lot, including 1H NMR spectra to confirm identity and structure, FT-IR profiles to detect functional group integrity, and HPLC chromatograms for purity and impurity profiling in line with International Council for Harmonisation (ICH) Q3C for solvent residues. Residual organics are quantified by GC, and elemental impurities are monitored using ICP-MS per ICH Q3D guidelines, guaranteeing the safety of the final product. Karl Fischer (KF) titration establishes consistent water content, critical to product stability. For customers pursuing regulatory submissions, full Drug Master File (DMF) support is provided.
Purification and isolation stages are designed for maximum removal of contaminants and byproducts, with a multi-stage washing sequence incorporating DMF, isopropanol, and finally chilled diethyl ether. Each washing step is performed under nitrogen to minimize moisture content and oxidative degradation. Once washing is complete, the product is transferred to a vacuum oven operating at 30 millibar (mbar) pressure and a controlled temperature of 40°C for 16 hours, ensuring thorough drying without compromising product integrity. This rigorous isolation sequence delivers peptide and oligonucleotide products with consistent lot-to-lot reproducibility. For more information about specific product lines and supply capabilities, comprehensive details are available through Technical Insights’ online product page.
In terms of technical parameters, scale-up experience shows that reactions are performed typically at batch sizes from 100 grams to multi-kilogram scale, with the automated synthesizers precisely controlling solvent addition, temperature, and cycle times. The bulk product is white to off-white in appearance, exhibits an HPLC retention time characteristic for each lot, and maintains a water content below 1.5% as standard. Analytical data confirm residual DMF levels well below ICH Q3C thresholds, and elemental impurity levels orders of magnitude beneath ICH Q3D limits.
Harnessing solid phase chemistry and advanced automation has allowed industry players like Technical Insights to deliver ultra-pure, high-yield peptides and oligonucleotides suitable for today’s most ambitious research and pharmaceutical applications. The technical rigor applied at every step—coupling, deprotection, washing, crystallization, and vacuum drying—ensures unmatched consistency and quality. Process validation, strict cGMP adherence, and comprehensive analytical support create the foundation for reliable, scalable manufacturing and global supply of these indispensable biomolecules.
Related Articles
